Assessment of atherosclerosis in oncologic patients using 18F-fluoride PET/CT

Kurata, Seiji; Tateishi, Ukihide; Shizukuishi, Kazuya; Yoneyama, Tomohiro; Hino, Ayako; Kaida, Hayato; Fujimoto, Kiminori; Ishibashi, Masatoshi; Inoue, Tomio

doi:10.1007/s12149-013-0706-8

Cited by 9 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since 18 F-NaF is taken up at sites of calcification, another interesting potential application may be in the assessment of atherosclerosis (49). In fact, use of PET with 18 F-FDG and 18F-NaF may provide important insight into the evolutionary phases of the atherosclerotic plaque from a vulnerable inflammatory state to development of plaque microcalcification, which then helps to understand the complex biology of plaque rupture (50).…”

Section: Benign Bone Joint and Other Diseasesmentioning

confidence: 99%

Sodium 18F-Fluoride PET/CT of Bone, Joint, and Other Disorders

Jadvar

Desai

Conti

2015

Seminars in Nuclear Medicine

113

View full text Add to dashboard Cite

The use of 18F-sodium fluoride (18F-NaF) with positron emission tomography-computed tomography (PET/CT) is increasing. This resurgence of an old tracer has been fueled by several factors including superior diagnostic performance over standard 99mTc-based bone scintigraphy, growth in the availability of PET/CT imaging systems, increase in the number of regional commercial distribution centers for PET radiotracers, the recent concerns about potential chronic shortages with 99mTc based radiotracers, and the recent decision by the Centers for Medicare and Medicaid Services to reimburse for 18F-NaF PET/CT for evaluation of patients with known or suspected bone metastases through the National Oncologic PET Registry. The major goal of this article is to review the current evidence on the diagnostic utility of 18F-NaF in the imaging assessment of bone and joint in a variety of clinical conditions.

show abstract

Section: Benign Bone Joint and Other Diseasesmentioning

confidence: 99%

Sodium 18F-Fluoride PET/CT of Bone, Joint, and Other Disorders

Jadvar

Desai

Conti

2015

Seminars in Nuclear Medicine

113

View full text Add to dashboard Cite

show abstract

“…There have already been several studies investigating the usefulness of NaF-18 PET for bone metastases (1,12,13), atherosclerosis (6,7,15), meningioma (22), and so on. In addition, several studies have compared Tc-99m-labeled bone scintigraphy and NaF-18 PET (11,14,19).…”

Section: Zusammenfassungmentioning

confidence: 99%

Differences in sodium fluoride-18 uptake in the normal skeleton depending on the location and characteristics of the bone

Nawata¹,

Kaneta

Ogawa³

et al. 2017

Nuklearmedizin

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the same study we also found that hypercholesterolemia, particularly high levels of total cholesterol and LDL-C, were significantly associated with aggressive metastatic PCa with an OR of 3.28 [137]. Recent studies indicated that hypertension, hypercholesterolemia, atherosclerosis, and a composite score of metabolic factors were associated with advanced PCa, biochemical recurrence and increased tumor mortality [28,93,139,148,149,150,151], as shown in Figure 2.…”

Section: Resultsmentioning

confidence: 88%

Metabolic Alterations, Aggressive Hormone-Naïve Prostate Cancer and Cardiovascular Disease: A Complex Relationship

et al. 2019

View full text Add to dashboard Cite

Background: Epidemiological studies suggest a possible relationship between metabolic alterations, cardiovascular disease and aggressive prostate cancer, however, no clear consensus has been reached. Objective: The aim of the study was to analyze the recent literature and summarize our experience on the association between metabolic disorders, aggressive hormone-naïve prostate cancer and cardiovascular disease. Method: We identified relevant papers by searching in electronic databases such as Scopus, Life Science Journals, and Index Medicus/Medline. Moreover, we showed our experience on the reciprocal relationship between metabolic alterations and aggressive prostate cancer, without the influence of hormone therapy, as well the role of coronary and carotid vasculopathy in advanced prostate carcinoma. Results: Prostate cancer cells have an altered metabolic homeostatic control linked to an increased aggressivity and cancer mortality. The absence of discrimination of risk factors as obesity, systemic arterial hypertension, diabetes mellitus, dyslipidemia and inaccurate selection of vascular diseases as coronary and carotid damage at initial diagnosis of prostate cancer could explain the opposite results in the literature. Systemic inflammation and oxidative stress associated with metabolic alterations and cardiovascular disease can also contribute to prostate cancer progression and increased tumor aggressivity. Conclusions: Metabolic alterations and cardiovascular disease influence aggressive and metastatic prostate cancer. Therefore, a careful evaluation of obesity, diabetes mellitus, dyslipidemia, systemic arterial hypertension, together with a careful evaluation of cardiovascular status, in particular coronary and carotid vascular disease, should be carried out after an initial diagnosis of prostatic carcinoma.

show abstract

Assessment of atherosclerosis in oncologic patients using 18F-fluoride PET/CT

Abstract: Our results suggest that (18)F-fluoride PET/CT might be a useful modality for detecting active mineral deposition sites of atherosclerosis in oncologic patients.

Cited by 9 publications

References 23 publications

Sodium 18F-Fluoride PET/CT of Bone, Joint, and Other Disorders

Sodium 18F-Fluoride PET/CT of Bone, Joint, and Other Disorders

Differences in sodium fluoride-18 uptake in the normal skeleton depending on the location and characteristics of the bone

Metabolic Alterations, Aggressive Hormone-Naïve Prostate Cancer and Cardiovascular Disease: A Complex Relationship

Contact Info

Product

Resources

About